ACTRN12607000077460
Recruiting
未知
Prospective Study to investigate the ability of the GSTP1 methylation assay to assess response to chemotherapy in patients with metastatic hormone-refractory prostate cancer
Dr Lisa Horvath0 sites150 target enrollmentJanuary 23, 2007
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Patients with Metastatic hormone-refractory prostate cancer
- Sponsor
- Dr Lisa Horvath
- Enrollment
- 150
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Histologically or cytologically confirmed adenocarcinoma of the prostate with clinical or radiological evidence of metastatic disease.2\. Confirmed Hormone\-refractory prostate cancer (HRPC) with a minimum of 4 weeks having elapsed between the withdrawal of antiandrogens and enrolment.3\. Patients must have a baseline serum Prostate\-specific antigen (PSA)\> 10 ng/ml (referred to as PSA \#1\), and two consecutive rises in serum PSA (referred to as PSA \#2 and PSA \#3\) greater than PSA \#1 with each test performed at least one week apart. If PSA \#3 is less than PSA \#2, the patient remains eligible provided a fourth PSA (PSA \#4\) is greater than PSA \#2\.4\. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0\-3\.5\. A neutrophil count of at least 1500 per cubic millimetre and a platelet count of at least 100 000 per cubic millimetre.6\. Normal bilirubin level and AST, ALT and serum creatinine no more than 1\.5 times the upper limit of the normal range. 7\. Castrate testosterone levels due to either luteinizing hormone\-releasing hormone (LHRH) agonists or orchidectomy.8\. Informed consent.
Exclusion Criteria
- •1\. Patients taking alternative therapies (eg Saw Palmetto, dehydroepiandrosterone (DHEA), lycopene, PC\-SPES, vitamin D, selenium).2\. Patients receiving chemotherapy other than Docetaxel or Mitoxantrone (eg cyclophosphamide).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Prospective study with the aim to investigate the biological relevance of fibrinolysis products and their use as prognostic and therapeutic biomarkers in SIRS and SEPSIS.A41.9Sepsis, unspecifiedDRKS00000215Klinik für Anästhesiologie, Intensivmedizin und SchmerztherapieKlinikum der J.W.-Goethe Universität150
Completed
Not Applicable
Prospective study to investigate the performance of cytokine removal of polymethyl methacrylate hemofilters with two different membrane surface areaSevere sepsis, Septic shockJPRN-UMIN000012164Department of Emergency and Critical Care Medicine, Chiba University, Graduate School of Medicine20
Active, not recruiting
Not Applicable
Central brain responses of sacral nerve stimulation in patients with faecal incontinenceFaecal incontinenceFunctional bowel disordersOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonNeurological - Studies of the normal brain and nervous systemACTRN12615001334594Professor Marc Gladman15
Completed
Not Applicable
An observational study to assess the ability of the thymine loading test to prospectively categorise patients with gastrointestinal or breast cancer who cannot tolerate fluoropyrimidine treatment.ACTRN12617001109392niversity of Auckland166
Not yet recruiting
Not Applicable
A prospective study to examine the effectiveness and safety of neuraminidase inhibitors in index cases with presumed pandemic influenza infectioPandemic influenzaInfection - Other infectious diseasesACTRN12608000176369ational Centre in HIV Epidemiology and Clinical Research (NCHECR)1,000